Gapping up
In reaction to strong earnings/guidance:
- SQNS +10.3%, CAG +4.3%
Other news:
- AKRO +34.5% (reports all AKR-001 dose groups met week 12 efficacy endpoints in NASH Phase 2a BALANCED study)
- MRSN +15.5% (reports updated data from Phase 1 dose escalation study of XMT-1536)
- CVLT +8.6% (Starboard (Jeffrey Smith) discloses 9.3% active stake)
- FANG +6.8% (reduces Q4 exit rate production guidance)
- CTMX +5.2% (achieves clinical milestone CX-2029 program, triggering a $40 mln payment from AbbVie)
- MT +4.9% (ArcelorMittal provides an update on the impact of COVID-19)
- RDS.A +4.2% (provides production guidance)
- CTSO +3.7% (cytokine adsorber has been approved to be marketed and sold in Mexico by the country's health authority)
- CSPR +2.7% (extends closure of North America retail stores)
- BA +2.4% (awarded $1.6 bln Navy contract modification)
- GWPH +2.1% (GW Pharma and Greenwich Biosciences announce FDA acceptance of sNDA filing with priority review for Epidiolex)
- PRQR +1.9% (reports positive findings from an interim analysis in the Phase 1/2 trial of QR-421a)
- NICE +1.3% (reports significant uptake in agents adapting their contact center schedules in response to the recent outbreak of COVID-19)
Analyst comments:
- APA +6.1% (upgraded to Neutral from Sell at UBS)
- ACAD +4.6% (upgraded to Buy from Neutral at Goldman )
- CRUS +3.6% (upgraded to Buy from Underperform at BofA/Merrill)
- CAKE +1.8% (upgraded to Buy from Hold at Gordon Haskett)
- HPE +1.5% (upgraded to Overweight from Equal Weight at Wells Fargo)